Use of Bristol-Myers Squibb’s Oral Abilify is Shifting to First-Line Treatment of Newly Diagnosed Schizophrenia Patients

BioTrends Research Group Releases Quarterly Schizophrenia Treatment Algorithms Analysis

EXTON, Penn.--()--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that analysis of U.S. longitudinal patient-level claims data reveals the use of Bristol-Myers Squibb’s oral Abilify as a first-line therapy for newly diagnosed schizophrenia patients continues to grow. With this increase, Abilify has the second-highest first-line patient share of newly diagnosed patients among atypical antipsychotics. According to Treatment Algorithms in Schizophrenia, oral risperidone (Janssen’s Risperdal, generics) continues to capture the greatest share of newly diagnosed schizophrenia patients among atypical antipsychotics, due to its availability as a generic. Atypical antipsychotics are the cornerstone treatment for schizophrenia and earn the largest percentage of patient share compared with other drug classes in the treatment of newly diagnosed patients.

“Abilify has a more favorable tolerability profile, with a lower risk of metabolic side effects compared with other atypicals such as Eli Lilly’s Zyprexa, and has shown efficacy in reducing the symptoms of depression; both factors may be reasons why physicians are turning to Abilify earlier in the treatment algorithm,” said Director Nicole Westphal, Ph.D.

BioTrends’ analysis also explores treatment patterns for recently treated schizophrenia patients, which captures patients treated in the third quarter of 2011 and reviews therapies in their treatment history. Among recently treated patients who switch to Abilify, 17.5 percent of patients progress from risperidone. Because of Abilify’s favorable side-effect profile, patients switching to Abilify may have exhibited tolerability issues with risperidone, particularly weight gain, hyperlipidemia and metabolic side effects.

The analysis is part of BioTrends’ Treatment Algorithms Insight series, which through examination of U.S. longitudinal patient-level claims data, provides exceptional insight into physicians’ prescribing trends, from diagnosis through multiple courses of treatment, for a specific disease. Quarterly data analysis reveals progression rates of patients through each line of therapy, the share each brand commands by line of therapy and add-versus-switch patterns to key brands.

About BioTrends Research Group

BioTrends Research Group provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Contacts

BioTrends Research Group
Lisa Osgood, 781-993-2606
losgood@dresourcesgroup.com
or
Decision Resources Group
Christopher Comfort, 781-993-2597
ccomfort@dresources.com

Release Summary

Abilify has the second-highest first-line patient share of newly diagnosed schizophrenia patients among atypical antipsychotics

Sharing

Contacts

BioTrends Research Group
Lisa Osgood, 781-993-2606
losgood@dresourcesgroup.com
or
Decision Resources Group
Christopher Comfort, 781-993-2597
ccomfort@dresources.com